Vivimed Labs secures Indian Govt nod to manufacture, market Favipiravir

Published On 2021-05-11 05:00 GMT   |   Update On 2021-05-11 12:31 GMT
Advertisement

Hyderabad: Drugmaker, Vivimed Labs Limited, has recently announced the receipt of Government of India (Director General of Health Services ) approval to Manufacture and market Favipiravir Tablet 200 mg & 400 mg under Vivimed's own brand name "Favulous" across India.

It is used for the treatment of mild to moderate cases of Covid-19. Favipiravir is one of the leading oral anti-viral treatment approved in various countries for the potential treatment of patients with mild to moderate Covid-19 disease.

Advertisement

Favipiravir registered highest sales in the month of April 2021. 

Commenting on the launch, Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd said, "With huge spike in Covid19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching "Favulous" at a competitive price to make the drug accessible to more and more patients thereby ensuring good health and reducing their financial burden. This is in line with Vivimed's commitment to be at forefront in India's fight against Covid-19."

The company will work closely with the various governments and medical community to ensure availability of "Favulous" to patients across the Country.

Read also: Vivimed labs gets Uzbekistan Govt nod for Orzole combi, Bilastin tablets

Established in 1991 in Hyderabad, India, Vivimed Labs has metamorphosed from a domestic small, entrepreneurial family-operated business to a global supplier of niche molecules and formulations across Healthcare, Pharmaceuticals and Specialty Chemicals consumers in nearly 50 countries.





Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News